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· The Project (Background, Motivation, Rationale)
Cyclotides are an emerging family of naturally occurring circular mini-proteins 
(~30-40 amino acids) characterized by six conserved Cys residues (forming 3 disulfide 
bridges) that  create a topologically unique structure designated as a  cyclic cysteine knot
(CCK). The cysteine knot motif, which is embedded within the macrocylic backbone, is 
described as two disulfide bridges that form a ring that is penetrated by the third disulfide 
bridge. The cyclic backbone and CCK motif together confer cyclotides with a remarkable 
stability and resistance to proteolytic, chemical, and thermal degradation. Further, 
cyclotides are functionally diverse and display a wide range of functions including 
uterotonic activity, trypsin inhibition, cytotoxicity, neurotensin binding, anti-HIV, 
antimicrobial, and insecticidal activity. Together, these characteristics make cyclotides 
attractive candidates for both drug design and agricultural applications, both in their 
native forms and as molecular scaffolds for the incorporation of novel bioactivities. [1]
The ability to manipulate production of cyclotides within biological systems is 
critical for mutagenesis studies, production of grafted products, and the mass production 
of cyclotides with novel activities. My adviser’s hope is to achieve this capability by 
employing recombinant DNA expression techniques to generate large combinatorial 
libraries of cyclotides. The advantage in creating a biosynthetic library (containing ~106-
1010 members/library vs. chemically based libraries with typical values ranging from 
~103-105 members/library) is that it can be lead to the in vivo application of biological 
screening and selection methodologies based on a specific clone’s ability to affect certain 
cellular processes.
**
MCoTI-II is a natural cyclotide isolated from the seeds of the spinal gourd 
Momordica cochinchinensis. It belongs to the trypsin inhibitory subfamily of cyclotides 
and is very different in sequence to the other cyclotide subfamilies. In fact, it is more 
homologous to a family of acyclic trypsin inhibitors known as squash protease inhibitors 
[2]. One factor for choosing MCoTI-II was that my adviser believed that we could take 
advantage of the protein’s ability to bind trypsin and therefore make isolation/purification 
of correctly folded MCoTI-II relatively straightforward compared to other cyclotides. 
With successful biosynthesis of MCoTI-II, the aspiration would be to then utilize the 
protein’s unique structural characteristics in order to evolve cyclotides capable of 
inhibiting bacterial toxins (e.g. Lethal Factor from Bacillus Anthracis) or other harmful 
bio-agents. 
**
Protein splicing is a naturally occurring, post-translational, self-processing that 
releases an internal protein sequence (Intein) from a protein precursor resulting in 
ligation of extein polypeptide sequences. Engineering of a naturally occurring intein and 
its subsequent inclusion into an expression vector allows for the biosynthesis of circular 
polypeptides through the intramolecular version of native chemical ligation (NCL) [3]. 
NCL is an extremely specific ligation reaction in which two fully unprotected 
polypeptides, one containing a C-terminal a-thioester group and the other a N-terminal 
Cys residue, react chemoselectively under neutral aqueous conditions with the formation 
of a native peptide bond. It’s well established that when these two reactive groups are 
located in the same precursor, the chemical ligation proceeds in an intramolecular manner 
thus resulting in the efficient formation of a circular polypeptide. Recent advances in 
protein engineering have also made possible the introduction of the C-terminal a-
thioester group and N-terminal Cys residue into recombinant proteins. These 
developments make the use of NCL between recombinant fragments possible and the 
general term for this technology is Expressed Protein Ligation (EPL). [4]
**
My project focused on the biosynthesis of the cyclotide MCoTI-II in E. coli based 
on the use of an engineered intein for in vivo circularization of a linear precursor via EPL. 
This is a necessary technology to apply in order to allow the backbone cyclization of the 
MCoTI-II linear precursors inside E. coli. Since MCoTI-II contains six conserved Cys 
residues, there are six potential linear precursors of the protein – each unique in which 
Cys residue acts as the N-terminus. As a result, it is possible that protein biosynthesis in 
E. coli could be achieved with varying degrees of success depending on which precursor 
is being used. Thus, my specific role in this project involved exploring the relative 
degrees of expression, folding, and cleavage by the engineered intein, for three of the 
MCoTI-II linear precursors. 
· The Project (My Specific Work)
As mentioned above, I worked with three different linear precursors of the 
cyclotide MCoTI-II, which I will designate MC-1, MC-4, and MC-6 (where the number 
indicates which Cys residue acts as the N-terminus and thus the point of cyclization). 
Most of the first half of my summer involved the molecular cloning of the three 
precursors above into each of two different expression vectors (pTXB1, pTYB1). Each 
expression vector contained an engineered intein and chitin-binding domain (CBD) 
upstream of the cloned gene, but differed in the identity of the engineered intein – thus, 
we could determine whether a specific intein could also influence biosynthesis success. 
Cloning each precursor involved typical molecular biology techniques such as DNA 
oligo hybridization, digestion, ligation, and colony PCR screening. Ultimately, I obtained 
2-3 positive clones for each precursor in each expression vector. 
The second half of my summer focused on the actual expression and subsequent 
analysis of MCoTI-II precursors. The goals during this time were to first determine 
whether biosynthesis of the protein was even plausible in E. coli, and then to begin 
determining how to optimally obtain the correctly folded (and thus active) protein. 
Expression and purification of each precursor (in either expression vector) involved 
techniques such as SDS-PAGE, sonication for cell lysis, and preparation of chitin bead 
columns used to trap proteins that were fused to the chitin binding domain mentioned 
earlier (these would be cyclotide-intein-CBD fusion products). Once precursors were 
isolated via chitin bead columns, I subjected small samples to mix with various thiols, 
causing cleavage of any remaining uncleaved cyclotide-intein fusions. Following that 
step, my adviser and I used RP-HPLC and ES-MS to characterize our products and to 
determine the presence of correctly folded MCoTI-II.  In addition, as mentioned earlier, 
we could further confirm the presence of correctly folded MCoTI-II by taking advantage 
of its native activity of trypsin inhibition. Therefore, I also prepared a trypsin-sepharose 
column through which we could run a sample and again characterize the binding products 
via RP-HPLC and ES-MS. 
· The Project (My Achievements, Contributions, etc.)
My first achievement was the successful molecular cloning of MC-1, MC-4, and 
MC-6 into two different expression vectors in a short period of time. Without this step, 
no further analysis could’ve been conducted. Next, I was able to confirm successful 
expression of MCoTI-II from the linear precursors MC-1 and MC-6 (both in pTXB1). As 
mentioned earlier, confirmation was achieved first characterizing thiol-cleaved chitin 
bound samples via SDS-PAGE, RP-HPLC, and ES-MS. Then I obtained even further 
evidence that we in fact had active protein using a trypsin-sepharose column. Products 
that bound to this particular column were analyzed using RP-HPLC and ES-MS, and an 
identical retention peak and mass associated with the correctly folded protein were again 
obtained. This set of experiments proved in fact that MCoTI-II could be successfully 
biosynthesized in the E. coli cytoplasm. When analyzing the same two precursors (MC-1, 
MC-6) in pTYB1, it appeared that in vivo cleavage was much better (one dominant SDS-
PAGE band rather than two) but overall expression was lower and we had a difficult time 
isolating and thus characterizing any protein that may have been present.  The final linear 
precursor, MC-4, had very little expression overall in both expression vectors and, even 
after chitin binding purification, SDS-PAGE bands were extremely faint. I even 
analyzed other MC-4-positive clones from the original ligation plating and the SDS-
PAGE results were consistent with the original faint bands observed. 
With successful expression of MCoTI-II from two different linear precursors, my 
next step was to begin thinking about optimization of in vivo protein biosynthesis. There 
are a number of different parameters that could be tuned in an attempt to optimize 
expression, degree of intein cleavage, etc. and these include: induction time, inducer 
concentration, and host cell line. My final contribution was transforming the plasmid 
containing the MC-6-intein-CBD fusion (in both expression vectors) into another host 
cell line that we think will potentially promote higher expression levels, and then 
subsequently performing a direct expression study with the original cell line used. I think 
my work has contributed a considerable amount to a MCoTI-II biosynthesis publication 
that my adviser hopes to have out by the end of this year. I have shown that we can 
successfully express an active folded protein in the E. coli cytoplasm and have also laid 
the groundwork for direct comparison between different linear precursors and different 
conditions for expression. These were both very big milestones in the project’s big 
picture. Some of the remaining work to be done prior to publication includes obtaining 
the cyclotide’s trypsin inhibition kinetics, as well as analyzing direct expression studies 
in which select parameters are tuned (see above) to determine the best possible conditions 
to achieve the highest degree of in vivo intein cleavage and the highest possible levels of 
expressed active protein. 
· Impact on academic/career planning
My internship experience didn’t particularly influence my academic or career 
planning. I am already two years into my graduate studies and therefore my academic 
plans were essentially set before I came to the lab. Further, I think I’d ultimately like to 
enter academia after I receive my degree so that I can have the opportunity both to do 
research and to teach. I think one major positive of this experience is my having the 
knowledge of another interesting area within my field and the ability to potentially apply 
some of the concepts I’ve learned about to future projects. Furthermore, I have now had 
the opportunity to complete a co-op in industry and an internship in a national laboratory. 
Taken with my graduate studies, I have had the chance to see how three very different 
types of organizations work, which is beneficial in helping choose different options in my 
career path. 
**
This summer, I attended a number of scientific seminars hosted by LLNL that 
covered a wide array of topics. I think the biggest benefit from attending these seminars 
was observing the most useful ways to give an effective presentation. One speaker may 
have been very good at slide layout while another excelled with his slide transitions, but 
ultimately, I was able to determine an approach in which I could combine the positive 
aspects from nearly every speaker in order to give an effective presentation of my own in 
the future. LLNL also had a weekly DHS required talk in which various projects within 
the lab were discussed. Topics included border security, a nuclear program overview, and 
small-scale PCR, but most times I felt as if a large part of the intern audience was left 
confused by the technical details discussed in the talks. I thought that the broad topics 
such as border security were by far the most valuable since everyone could more or less 
comprehend the material and also form opinions that led to interesting dialogue about 
ideas that most of us generally never have an opportunity to discuss. For this reason, I 
also thought that the DHS talk in which Maureen McCarthy spoke to LLNL and Sandia 
interns was above average because, although she was still theoretically giving a talk, it 
felt more like a discussion forum on an assortment of broad but important topics. 
Unsurprisingly, it was more engaging to be a part of talks that led to interesting questions 
and debate rather than ones where only a handful of interns could grasp the material or 
where the attention to detail began to outweigh the big picture. 
· Ideas for future DHS Research 
I think a few main areas of research that could receive more attention are: border 
security, treating persons afflicted with bioterror agents, and high-throughput screening 
procedures at airports. 
I think that the DHS talk on border security this summer really opened my eyes 
(and others as well) to the lack of an efficient and reliable means to effectively secure our 
borders. We learned that most of our southern border is unprotected and those small areas 
that are being observed are normally by just 1-2 officers who are not fully equipped to 
deal with a lot of the potential encounters that could occur. In addition, we were told that 
due to the mainly rural nature of the northern border, it becomes, in essence, impossible 
to secure.  I feel that significant research should be committed to improve upon what 
appears to be extreme shortcomings in securing our borders. This could mean simply 
increasing manpower along our borders, looking into more effective preventative means, 
or changing the approach that is taken with those who wish to illegally enter the country. 
For instance, we heard that in most cases, all it takes is persistence by those who want to 
cross the border since most times, if caught, they are simply sent back to their country 
only to basically try again and again. By whatever means, I think this is definitely an area 
that should receive more research attention; both hard science-based and social science-
based. 
Additionally, it appeared to me that a lot of research is being done in order to 
potentially screen for bioterror agents in large areas (there were multiple talks this 
summer about small-scale PCR for instance), but I think we should also be devoting more 
resources into treating those who do potentially become affected by a bio-agent. I can’t 
remember any seminars or DHS talks that were concerned with developing vaccines or 
antibodies or therapeutics towards bioterror agents, although my particular project this 
summer could be potentially applied towards these means in the long run. It seemed, 
based on the seminars and talks I attended this summer, that there was much more focus 
on identifying or screening for the presence of agents relative to actually treating them if 
necessary. But again, I can only say this based on the ten-week sample of talks I was able 
to attend. 
Finally, in light of recent current events, I think a stronger focus should be placed 
on large-scale high throughput screening not only of bio-agents, but also other potential 
destructive or debilitating forces as well, specifically in airports. Research could be 
placed into optimizing a process to screen passenger carry-on items such as water bottles 
or shampoo bottles, for example, to test for explosive materials. I think the public would 
be in favor of a high-throughput screening process that would, in a best case scenario, 
ensure their safety but also not cause extremely long airport delays. Extensive research 
must be placed creating some sort of screening protocol that could ultimately encompass 
a broad range of materials – not just liquids for example. Only with said process in tact, 
can we truly secure our commercial flights, since they seem to continue to be targeted. 
In summary, I think that DHS should focus more attention towards securing our 
nation’s borders (both land and sea), developing treatments against the wide scope of 
bioterrorist agents that exist, and securing our commercial flights against an ever 
expanding repertoire of threats.  
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